BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Felipez LM, Gokhale R, Tierney MP, Kirschner BS. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr. 2012;54:28-33. [PMID: 21681114 DOI: 10.1097/mpg.0b013e318228349e] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Manuc TE, Manuc MM, Diculescu MM. Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. Clin Exp Gastroenterol 2016;9:59-70. [PMID: 27042137 DOI: 10.2147/CEG.S53381] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
2 Allen PB, Peyrin-Biroulet L. Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. Expert Rev Clin Immunol. 2016;12:741-749. [PMID: 26900725 DOI: 10.1586/1744666x.2016.1154789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
4 Wang L, Hong Y, Wu J, Leung YK, Huang Y. Efficacy of thalidomide therapy in pediatric Crohn’s disease with evidence of tuberculosis. World J Gastroenterol 2017; 23(43): 7727-7734 [PMID: 29209113 DOI: 10.3748/wjg.v23.i43.7727] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease. Intest Res 2017;15:318-27. [PMID: 28670228 DOI: 10.5217/ir.2017.15.3.318] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
6 Bramuzzo M, Ventura A, Martelossi S, Lazzerini M. Thalidomide for inflammatory bowel disease: Systematic review. Medicine (Baltimore) 2016;95:e4239. [PMID: 27472695 DOI: 10.1097/MD.0000000000004239] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 5.6] [Reference Citation Analysis]
7 Hu H, Wang X, Liu S. Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. Medicine (Baltimore) 2016;95:e4799. [PMID: 27603389 DOI: 10.1097/MD.0000000000004799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 Marcil V, Levy E, Amre D, Bitton A, Sant'Anna AMGA, Szilagy A, Sinnett D, Seidman EG. A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping? Inflamm Bowel Dis 2019;25:1428-41. [PMID: 30793155 DOI: 10.1093/ibd/izy403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
9 Vecchi Brumatti L, Marcuzzi A, Tricarico PM, Zanin V, Girardelli M, Bianco AM. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. Molecules. 2014;19:21127-21153. [PMID: 25521115 DOI: 10.3390/molecules191221127] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 8.8] [Reference Citation Analysis]
10 Rumore MM. Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks. J Pediatr Pharmacol Ther 2016;21:36-53. [PMID: 26997928 DOI: 10.5863/1551-6776-21.1.36] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]